Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS 2 | JAN 08 | CHEMLIST enhanced with New Zealand Inventory of Chemicals |
| NEWS 3 | JAN 16 | CA/CAplus Company Name Thesaurus enhanced and reloaded |
| NEWS 4 | JAN 16 | IPC version 2007.01 thesaurus available on STN |
| NEWS 5 | JAN 16 | WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data |
| NEWS 6 | JAN 22 | CA/CAplus updated with revised CAS roles |
| NEWS 7 | JAN 22 | CA/CAplus enhanced with patent applications from India |
| NEWS 8 | JAN 29 | PHAR reloaded with new search and display fields |
| NEWS 9 | JAN 29 | CAS Registry Number crossover limit increased to 300,000 in multiple databases |
| NEWS 10 | FEB 15 | PATDPASPC enhanced with Drug Approval numbers |
| NEWS 11 | FEB 15 | RUSSIAPAT enhanced with pre-1994 records |
| NEWS 12 | FEB 23 | KOREAPAT enhanced with IPC 8 features and functionality |
| NEWS 13 | FEB 26 | MEDLINE reloaded with enhancements |
| NEWS 14 | FEB 26 | EMBASE enhanced with Clinical Trial Number field |
| NEWS 15 | FEB 26 | TOXCENTER enhanced with reloaded MEDLINE |
| NEWS 16 | FEB 26 | IFICDB/IFIPAT/IFIUDB reloaded with enhancements |
| NEWS 17 | FEB 26 | CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases |
| NEWS 18 | MAR 15 | WPIDS/WPIX enhanced with new FRAGHITSTR display format |
| NEWS 19 | MAR 16 | CASREACT coverage extended |
| NEWS 20 | MAR 20 | MARPAT now updated daily |
| NEWS 21 | MAR 22 | LWPI reloaded |
| NEWS 22 | MAR 30 | RDISCLOSURE reloaded with enhancements |
| NEWS 23 | APR 02 | JICST-EPLUS removed from database clusters and STN |
| NEWS 24 | APR 30 | GENBANK reloaded and enhanced with Genome Project ID field |
| NEWS 25 | APR 30 | CHEMCATS enhanced with 1.2 million new records |
| NEWS 26 | APR 30 | CA/CAplus enhanced with 1870-1889 U.S. patent records |
| NEWS 27 | APR 30 | INPADOC replaced by INPADOCDB on STN |
| NEWS 28 | MAY 01 | New CAS web site launched |

| | |
|---|---|
| NEWS EXPRESS | NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006. |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 |

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:11:19 ON 01 MAY 2007

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 17:11:27 ON 01 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 APR 2007  HIGHEST RN 933825-30-0
DICTIONARY FILE UPDATES:  30 APR 2007  HIGHEST RN 933825-30-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10596495a.str
```





chain nodes :
1 2 3 10 11 13 14 15 16
ring nodes :
4 5 6 7 8 9 18 19 20 21 22 23 24 25 26
ring/chain nodes :
17
chain bonds :
1-2 1-3 1-4 1-18 5-14 6-13 7-10 8-16 9-15 10-11 10-17
ring bonds :
4-5 4-9 5-6 6-7 7-8 8-9 18-19 18-22 19-20 20-21 21-22 21-23 22-26
23-24 24-25 25-26
exact/norm bonds :
1-2 1-3 1-4 1-18 5-14 6-13 7-10 8-16 9-15 10-11 10-17 18-19 18-22
19-20 20-21 21-22 21-23 22-26 23-24 24-25 25-26
normalized bonds :
4-5 4-9 5-6 6-7 7-8 8-9
isolated ring systems :
containing 4 : 18 :

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom

```
L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
G1 C,N

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 17:11:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     3104 TO ITERATE

 64.4% PROCESSED     2000 ITERATIONS                                 36 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        58739 TO    65421
PROJECTED ANSWERS:             669 TO     1565

L2            36 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 17:12:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    62918 TO ITERATE

100.0% PROCESSED    62918 ITERATIONS                                673 ANSWERS
SEARCH TIME: 00.00.01

L3           673 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   172.55     172.76

FILE 'CAPLUS' ENTERED AT 17:12:24 ON 01 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 1 May 2007 VOL 146 ISS 19
FILE LAST UPDATED: 30 Apr 2007 (20070430/ED)



=>

=> s l3 full
L4 10 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1190019 CAPLUS
DOCUMENT NUMBER: 146:114231
TITLE: Discovery and initial development of a novel class of antibacterials: Inhibitors of Staphylococcus aureus transcription/translation
AUTHOR(S): Larsen, Scott D.; Hester, Matthew R.; Ruble, J. Craig; Kamilar, Gregg M.; Romero, Donna L.; Wakefield, Brian; Melchior, Earline P.; Sweeney, Michael T.; Marotti, Keith R.
CORPORATE SOURCE: Medicinal Chemistry and Infectious Diseases Biology, Pharmacia Corporation, Kalamazoo, MI, 49001, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(24), 6173-6177
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:114231
AB The novel bacterial transcription/translation (TT) inhibitor 1 was identified through a combination of high throughput screening and exploratory medicinal chemical Initial optimization of the anthranilic acid moiety and sulfonamide amine diversity was accomplished via 1- and two-dimensional solution phase libraries, resulting in an improvement in the MIC of the lead from 64 to 8 μg/mL (compound 41). Subsequent modification of the central aromatic ring and further refinement of the sulfonamide amines required the development of a solid phase route on Wang resin. The resulting libraries generated a number of potent antibacterials with MICs of ≤1 μg/mL (e.g., 10b, 12, and 13). During the course of this work, it became apparent that the antibacterial activity of the series is not fully correlated with TT inhibition, suggesting that at least one addnl. mechanism of action is operative.
IT 668265-57-4P 918666-79-2P 918666-80-5P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU

(Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(Discovery and initial development of a novel class of antibacterials: Inhibitors of Staphylococcus aureus transcription/translation)

RN 668265-57-4 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(6-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (CA INDEX NAME)



RN 918666-79-2 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (CA INDEX NAME)



RN 918666-80-5 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(2,3-dihydro-3,3-dimethyl-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:638844 CAPLUS
DOCUMENT NUMBER: 143:133274
TITLE: Preparation of arylsulfonyl-substituted indoles as CB1 receptor modulators
INVENTOR(S): Allen, Jennifer Rebecca; Amegadzie, Albert Kudzovi; Gardinier, Kevin Matthew; Gregory, George Stuart; Hitchcock, Steven Andrew; Hoogestraat, Paul J.; Jones, Winton Dennis, Jr.; Smith, Daryl Lynn
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 204 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2005066126 | A1 | 20050721 | WO 2004-US39763 | | 20041213 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| AU 2004312311 | A1 | 20050721 | AU 2004-312311 | | 20041213 |
| CA 2549396 | A1 | 20050721 | CA 2004-2549396 | | 20041213 |
| EP 1699761 | A1 | 20060913 | EP 2004-812310 | | 20041213 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU | | | | | |
| BR 2004018079 | A | 20070417 | BR 2004-18079 | | 20041213 |
| US 2007088018 | A1 | 20070419 | US 2006-596495 | | 20060615 |
| NO 2006003381 | A | 20060920 | NO 2006-3381 | | 20060721 |
| PRIORITY APPLN. INFO.: | | | US 2003-532247P | P | 20031223 |
| | | | WO 2004-US39763 | W | 20041213 |

OTHER SOURCE(S): MARPAT 143:133274
GI



I

AB Title compds. I [the nitrogen containing ring = indolyl, pyrrolopyridinyl, etc.; X = amino, etc.] are prepared For instance,. N-(4-Fluorobenzyl)-4-[(3-phenylpyrrolo[3,2-c]pyridine-1-yl)sulfonyl]benzamide is prepared from 3-Phenyl-1H-pyrrolo[3,2-c]pyridine (preparation given) and 4-(4-Fluorobenzylcarbamoyl)benzenesulfonyl chloride (THF, KOBu-t, 16 h). Compds. of the invention exhibit IC50 ≤ 5 μM for the CB1 and CB2 receptors. I are useful in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease and schizophrenia. I are also useful for the treatment of substance abuse disorders, particularly to opiates, alc., and nicotine and for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

IT 859164-92-4P, N-(4-Fluorobenzyl)-4-[3-(3-oxocyclopentyl)indole-1-sulfonyl]benzamide 859165-01-8P, N-(4-Fluorobenzyl)-4-(3-methylindole-1-sulfonyl)benzamide 859165-25-6P, 4-[3-(2,3-Dihydrofuran-3-yl)indole-1-sulfonyl]-N-(4-fluorobenzyl)benzamide 859165-28-9P, N-(4-Fluorobenzyl)-4-[(3-phenyl-2,3-dihydroindole-1-yl)sulfonyl]benzamide 859165-32-5P, [3-(Aminomethyl)azetidin-1-yl][4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859165-33-6P,

[1-[4-(3-Phenylindole-1-sulfonyl)benzoyl]azetidin-3-ylmethyl]carbamic acid tert-butyl ester 859165-34-7P, N-(Azetidin-3-yl)-4-(3-phenylindole-1-sulfonyl)benzamide 859165-35-8P, 3-[4-(3-Phenylindole-1-sulfonyl)benzoylamino]azetidine-1-carboxylic acid tert-butyl ester 859165-36-9P, (R)-(3-Aminopyrrolidin-1-yl)[4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859165-37-0P, (R)-[1-[4-(3-Phenylindole-1-sulfonyl)benzoyl]pyrrolidin-3-yl]carbamic acid tert-butyl ester 859165-38-1P, (S)-(3-Aminopyrrolidin-1-yl)[4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859165-39-2P, (S)-[1-[4-(3-Phenylindole-1-sulfonyl)benzoyl]pyrrolidin-3-yl]carbamic acid tert-butyl ester 859165-40-5P, (3-Aminoazetidin-1-yl)[4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859165-41-6P, [1-[4-(3-Phenylindole-1-sulfonyl)benzoyl]azetidin-3-yl]carbamic acid tert-butyl ester 859165-50-7P, trans-N-(2-Hydroxycyclohexylmethyl)-4-(3-phenylindole-1-sulfonyl)benzamide 859165-57-4P, cis-N-(2-Hydroxycyclohexyl)-4-(3-phenylindole-1-sulfonyl)benzamide 859166-08-8P, 4-(3-Phenylindole-1-sulfonyl)-N-[(tetrahydrofuran-3-yl)methyl]benzamide 859166-11-3P, 4-(3-Cyclopentylindole-1-sulfonyl)-N-[(tetrahydropyran-2-yl)methyl]benzamide 859166-32-8P, (3-Hydroxyazetidin-1-yl)[4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859166-77-1P, N-(4-Fluorobenzyl)-4-[3-(pyrimidin-2-yl)indole-1-sulfonyl]benzamide 859166-78-2P, N-(4-Fluorobenzyl)-4-[3-(pyrimidin-5-yl)indole-1-sulfonyl]benzamide 859166-84-0P, 4-(3-Cyclopentylindole-1-sulfonyl)-N-(4-fluorobenzyl)benzamide 859166-85-1P, N-[(5-Fluoropyridin-3-yl)methyl]-4-(3-phenylindole-1-sulfonyl)benzamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of arylsulfonyl-substituted indoles as CB1 receptor modulators)

RN 859164-92-4 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(3-oxocyclopentyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 859165-01-8 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[(3-methyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 859165-25-6 CAPLUS
CN Benzamide, 4-[[3-(2,3-dihydro-3-furanyl)-1H-indol-1-yl]sulfonyl]-N-[(4-

fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859165-28-9 CAPLUS
CN Benzamide, 4-[(2,3-dihydro-3-phenyl-1H-indol-1-yl)sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859165-32-5 CAPLUS
CN 3-Azetidinemethanamine, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-33-6 CAPLUS
CN Carbamic acid, [[1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-3-azetidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 859165-34-7 CAPLUS
CN Benzamide, N-3-azetidinyl-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-35-8 CAPLUS
CN 1-Azetidinecarboxylic acid, 3-[[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 859165-36-9 CAPLUS
CN 3-Pyrrolidinamine, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859165-37-0 CAPLUS
CN Carbamic acid, [(3R)-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859165-38-1 CAPLUS
CN 3-Pyrrolidinamine, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859165-39-2 CAPLUS
CN Carbamic acid, [(3S)-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859165-40-5 CAPLUS
CN 3-Azetidinamine, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-41-6 CAPLUS
CN Carbamic acid, [1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-3-azetidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 859165-50-7 CAPLUS
CN Benzamide, N-[[(1R,2S)-2-hydroxycyclohexyl]methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 859165-57-4 CAPLUS
CN Benzamide, N-[(1R,2S)-2-hydroxycyclohexyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 859166-08-8 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-11-3 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-32-8 CAPLUS
CN 3-Azetidinol, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859166-77-1 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(2-pyrimidinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-78-2 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(5-pyrimidinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-84-0 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-85-1 CAPLUS
CN Benzamide, N-[(5-fluoro-3-pyridinyl)methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



IT 394228-83-2P, [4-((2,3-Dihydroindole-1-yl)sulfonyl)phenyl](morpholin-4-yl)methanone 394228-85-4P, [4-((2,3-Dihydroindole-1-yl)sulfonyl)phenyl](piperidin-1-yl)methanone 439128-75-3P, [4-((2,3-Dihydroindole-1-yl)sulfonyl)phenyl](4-phenylpiperazin-1-yl)methanone 859164-91-3P, N-(4-Fluorobenzyl)-4-[(3-phenylpyrrolo[3,2-c]pyridine-1-yl)sulfonyl]benzamide 859164-93-5P, N-(4-Fluorobenzyl)-4-(3-propylindole-1-sulfonyl)benzamide 859164-94-6P, N-(4-Fluorobenzyl)-4-[(pyrrolo[2,3-b]pyridine-1-yl)sulfonyl]benzamide 859164-95-7P, N-(4-Fluorobenzyl)-4-(indole-1-sulfonyl)benzamide 859164-97-9P, N-(4-Fluorobenzyl)-4-[3-(2-methoxycyclohexyl)indole-1-sulfonyl]benzamide 859164-98-0P, N-(4-Fluorobenzyl)-4-[3-(1-methylpiperidin-4-yl)indazole-1-sulfonyl]benzamide 859164-99-1P, N-(4-Fluorobenzyl)-4-(3-phenylindazole-1-sulfonyl)benzamide 859165-00-7P, 4-[(2,3-Dihydroindole-1-yl)sulfonyl]-N-(4-fluorobenzyl)benzamide 859165-02-9P, 4-(3-Acetylindole-1-sulfonyl)-N-(4-fluorobenzyl)benzamide 859165-03-0P, N-(4-Fluorobenzyl)-4-[[3-(trifluoromethyl)indazole-1-yl]sulfonyl]benzamide 859165-05-2P, N-(4-Fluorobenzyl)-4-[3-[(4-methylpiperazine-1-yl)carbonyl]indole-1-sulfonyl]benzamide 859165-06-3P,

N-(4-Fluorobenzyl)-4-[3-(1-methylpiperidin-2-yl)indole-1-sulfonyl]benzamide 859165-07-4P, N-(4-Fluorobenzyl)-4-[3-[2-(morpholin-4-yl)acetyl]indole-1-sulfonyl]benzamide 859165-08-5P, N-(4-Fluorobenzyl)-4-[3-[(tetrahydrofuran-2-yl)carbonyl]indole-1-sulfonyl]benzamide 859165-09-6P, N-(4-Fluorobenzyl)-4-[3-(1-methylpiperidin-4-yl)indole-1-sulfonyl]benzamide 859165-10-9P, N-(4-Fluorobenzyl)-4-[3-(3,3-difluorocyclopentyl)indole-1-sulfonyl]benzamide 859165-11-0P, 4-[(3-Ethyl-3-methyl-2,3-dihydroindole-1-yl)sulfonyl]-N-(4-fluorobenzyl)benzamide 859165-17-6P, N-(4-Fluorobenzyl)-4-[3-(morpholin-4-yl)indole-1-sulfonyl]benzamide 859165-18-7P, N-(4-Fluorobenzyl)-4-[3-(4-methylpiperazin-1-yl)indole-1-sulfonyl]benzamide 859165-19-8P, N-(4-Fluorobenzyl)-4-[3-(piperidin-1-yl)indole-1-sulfonyl]benzamide 859165-20-1P, 4-(3-tert-Butylindole-1-sulfonyl)-N-(4-fluorobenzyl)benzamide 859165-21-2P, N-(4-Fluorobenzyl)-4-[3-(1-methylcyclopentyl)indole-1-sulfonyl]benzamide 859165-22-3P, N-(4-Fluorobenzyl)-4-[3-(piperidin-1-yl)indazole-1-sulfonyl]benzamide 859165-23-4P, N-(4-Fluorobenzyl)-4-[3-(morpholin-4-yl)indazole-1-sulfonyl]benzamide 859165-24-5P, N-(4-Fluorobenzyl)-4-[3-(3-hydroxycyclopentyl)indole-1-sulfonyl]benzamide 859165-27-8P, N-(4-Fluorobenzyl)-4-[3-(tetrahydrofuran-3-yl)indole-1-sulfonyl]benzamide 859165-29-0P, (R)-N-(4-Fluorobenzyl)-4-[(3-phenyl-2,3-dihydroindole-1-yl)sulfonyl]benzamide 859165-30-3P, (S)-N-(4-Fluorobenzyl)-4-[(3-phenyl-2,3-dihydroindole-1-yl)sulfonyl]benzamide 859165-31-4P, N-(4-Fluorobenzyl)-4-[3-(tetrahydropyran-4-yl)indole-1-sulfonyl]benzamide 859165-42-7P, 4-(3-Phenylindole-1-sulfonyl)-N-[(pyrazin-2-yl)methyl]benzamide 859165-43-8P, N-(4-Cyanobenzyl)-4-[3-(tetrahydropyran-4-yl)indole-1-sulfonyl]benzamide 859165-44-9P, (2-Phenylazetidin-1-yl)[4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859165-45-0P, 4-(3-Phenylindole-1-sulfonyl)-N-[(pyrimidin-2-yl)methyl]benzamide 859165-46-1P, [4-(3-Phenylindole-1-sulfonyl)phenyl](3,4,5,6-tetrahydro-[4,4']bipyridinyl-1-yl)methanone 859165-47-2P, 4-(3-Phenylindole-1-sulfonyl)-N-[(pyridin-3-yl)methyl]benzamide hydrochloride 859165-48-3P, N-[(5-Fluoropyridin-3-yl)methyl]-4-(3-phenylindole-1-sulfonyl)benzamide hydrochloride 859165-49-4P, N-[(5-Fluoropyridin-2-yl)methyl]-4-(3-phenylindole-1-sulfonyl)benzamide hydrochloride 859165-51-8P, cis-N-(2-Hydroxycyclohexylmethyl)-4-(3-phenylindole-1-sulfonyl)benzamide 859165-52-9P, (S)-4-((3-Phenylindole-1-yl)sulfonyl)-N-((tetrahydrofuran-2-yl)methyl)benzamide 859165-53-0P, (R)-4-(3-Phenylindole-1-sulfonyl)-N-((tetrahydrofuran-2-yl)methyl)benzamide 859165-54-1P , 4-(3-Phenylindole-1-sulfonyl)-N-[(pyridin-2-yl)methyl]benzamide hydrochloride 859165-55-2P, 4-(3-Phenylindole-1-sulfonyl)-N-[(pyridin-4-yl)methyl]benzamide hydrochloride 859165-56-3P, trans-N-(2-Hydroxycyclohexyl)-4-(3-phenylindole-1-sulfonyl)benzamide 859165-59-6P, (4-Benzylpiperidin-1-yl)[4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859165-60-9P, (4,4-Difluoropiperidin-1-yl)[4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859165-61-0P, [4-(3-Phenylindole-1-sulfonyl)phenyl](piperidin-1-yl)methanone 859165-62-1P, [4-(3-Phenylindole-1-sulfonyl)phenyl](pyrrolidin-1-yl)methanone 859165-63-2P, 4-(3-Phenylindole-1-sulfonyl)-N-(tetrahydropyran-4-yl)benzamide 859165-64-3P, N,N-Dimethyl-4-(3-phenylindole-1-sulfonyl)benzamide 859165-65-4P , 1-[4-(3-Phenylindole-1-sulfonyl)benzoyl]piperidin-4-one 859165-66-5P, (3-Hydroxypiperidin-1-yl)[4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859165-67-6P, (Morpholin-4-yl)[4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859165-68-7P, (2-Hydroxymethylpiperidin-1-yl)[4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859165-69-8P, (3-Hydroxymethylpiperidin-1-yl)[4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859165-70-1P, trans-N-(4-Hydroxycyclohexyl)-4-(3-phenylindole-1-sulfonyl)benzamide 859165-71-2P, 4-(3-Phenylindole-1-sulfonyl)-N-

[(pyridazin-3-yl)methyl]benzamide 859165-72-3P,
N-[1-(4-Fluorophenyl)piperidin-4-yl]-4-(3-phenylindole-1-
sulfonyl)benzamide 859165-73-4P, 4-(3-Phenylindole-1-sulfonyl)-N-
[(1-phenylpiperidin-4-yl)methyl]benzamide 859165-74-5P,
(R)-N-[1-(4-Fluorophenyl)pyrrolidin-3-yl]-4-(3-phenylindole-1-
sulfonyl)benzamide 859165-75-6P, (S)-N-[1-(4-
Fluorophenyl)pyrrolidin-3-yl]-4-(3-phenylindole-1-sulfonyl)benzamide
859165-76-7P, N-[1-(4-Fluorophenyl)azetidin-3-yl]-4-(3-
phenylindole-1-sulfonyl)benzamide 859165-77-8P,
4-(3-Phenylindole-1-sulfonyl)-N-[(tetrahydropyran-4-yl)methyl]benzamide
859165-78-9P, N-(2-Methoxyethyl)-4-(3-phenylindole-1-
sulfonyl)benzamide 859165-79-0P, N-(2-Isopropoxyethyl)-4-(3-
phenylindole-1-sulfonyl)benzamide 859165-80-3P,
N-(2-Ethoxyethyl)-4-(3-phenylindole-1-sulfonyl)benzamide
859165-81-4P, 4-[[4-(3-Phenylindole-1-
sulfonyl)benzoylamino]methyl]benzoic acid methyl ester
859165-82-5P, N-(3-Methoxybenzyl)-4-(3-phenylindole-1-
sulfonyl)benzamide 859165-83-6P, N-(4-Dimethylaminobenzyl)-4-(3-
phenylindole-1-sulfonyl)benzamide 859165-84-7P,
N-(4-Aminobenzyl)-4-(3-phenylindole-1-sulfonyl)benzamide
859165-85-8P, [2-[(Phenylamino)methyl]pyrrolidin-1-yl][4-(3-
phenylindole-1-sulfonyl)phenyl]methanone 859165-87-0P,
2-[1-[4-(3-Phenylindole-1-sulfonyl)benzoyl]azetidin-3-ylmethyl]isoindole-
1,3-dione 859165-89-2P, N-Cyclobutyl-4-(3-phenylindole-1-
sulfonyl)benzamide 859165-90-5P, 3-[[4-(3-Phenylindole-1-
sulfonyl)benzoylamino]methyl]azetidine-1-carboxylic acid methyl ester
859165-91-6P, (3-Hydroxymethylazetidin-1-yl)[4-(3-phenylindole-1-
sulfonyl)phenyl]methanone 859165-92-7P, (R)-N-(Tetrahydrofuran-2-
ylmethyl)-4-[3-(tetrahydropyran-4-yl)indole-1-sulfonyl]benzamide
859165-93-8P, N-(2-Methoxycyclohexyl)-4-(3-phenylindole-1-
sulfonyl)benzamide 859165-94-9P, N-[1-(4-Fluorophenyl)pyrrolidin-
3-yl]-4-(3-phenylindole-1-sulfonyl)benzamide 859165-95-0P,
3-[4-(3-Phenylindole-1-sulfonyl)benzoylamino]pyrrolidine-1-carboxylic acid
methyl ester 859165-96-1P, [4-(3-Fluorophenyl)piperidin-1-yl][4-
(3-phenylindole-1-sulfonyl)phenyl]methanone 859165-97-2P,
4-[3-(2-Fluoropyridin-3-yl)indole-1-sulfonyl]-N-[(tetrahydropyran-4-
yl)methyl]benzamide 859165-98-3P, N-Cyclobutyl-4-[3-(2-
fluoropyridin-3-yl)indole-1-sulfonyl]benzamide 859165-99-4P,
N-Cyclopropylmethyl-4-[3-(2-fluoropyridin-3-yl)indole-1-sulfonyl]benzamide
859166-00-0P, 4-[3-(6-Fluoropyridin-3-yl)indole-1-sulfonyl]-N-
[(tetrahydropyran-4-yl)methyl]benzamide 859166-01-1P,
N-Cyclopropylmethyl-4-[3-(6-fluoropyridin-3-yl)indole-1-sulfonyl]benzamide
859166-02-2P, 4-(3-Cyclopentylindole-1-sulfonyl)-N-
[(cyclopropyl)methyl]benzamide 859166-03-3P,
4-(3-Cyclopentylindole-1-sulfonyl)-N-cyclobutylbenzamide
859166-04-4P, (Azetidin-1-yl)[4-(3-cyclopentylindole-1-
sulfonyl)phenyl]methanone 859166-05-5P, N-(5-Cyanopyridin-3-
ylmethyl)-4-(3-phenylindole-1-sulfonyl)benzamide 859166-06-6P,
(R)-4-(3-Cyclopentylindole-1-sulfonyl)-N-[(tetrahydrofuran-2-
yl)methyl]benzamide 859166-07-7P, N-Cyclopropylmethyl-4-[3-
(tetrahydropyran-4-yl)indole-1-sulfonyl]benzamide 859166-09-9P,
N-(4-Cyanobenzyl)-4-[3-(cyclopentyl)indole-1-sulfonyl]benzamide
859166-10-2P, N-(4-Cyanobenzyl)-4-(3-cyclopropylindole-1-
sulfonyl)benzamide 859166-12-4P, N-Isobutyl-4-(3-phenylindole-1-
sulfonyl)benzamide 859166-13-5P, N-(3-Methylbutyl)-4-((3-
phenylindole-1-yl)sulfonyl)benzamide 859166-14-6P,
N-(2-Methylbutylamine)-4-(3-phenylindole-1-sulfonyl)benzamide
859166-15-7P, 4-(3-Cyclopropylindole-1-sulfonyl)-N-[(5-
fluoropyridin-2-yl)methyl]benzamide 859166-16-8P,
4-(3-Cyclopropylindole-1-sulfonyl)-N-[(tetrahydropyran-4-
yl)methyl]benzamide 859166-17-9P, 4-(3-Cyclopropylindole-1-
sulfonyl)-N-(2-isopropoxyethyl)benzamide 859166-18-0P,
N-(4-Cyanobenzyl)-4-(3-phenylindole-1-sulfonyl)benzamide

859166-19-1P, N-[(5-Fluoropyridin-2-yl)methyl]-4-[3-(tetrahydropyran-4-yl)indole-1-sulfonyl]benzamide 859166-20-4P, 4-[3-(Tetrahydropyran-4-yl)indole-1-sulfonyl]-N-[(tetrahydropyran-4-yl)methyl]benzamide 859166-21-5P, N-Cyclobutyl-4-[3-(tetrahydropyran-4-yl)indole-1-sulfonyl]benzamide 859166-22-6P, N-[(5-Fluoropyridin-3-yl)methyl]-4-[3-(tetrahydropyran-4-yl)indole-1-sulfonyl]benzamide 859166-23-7P, N-[(Cyclopropyl)methyl]-4-(3-phenylindole-1-sulfonyl)benzamide 859166-24-8P, 4-(3-Cyclopentylindole-1-sulfonyl)-N-[(pyridin-3-yl)methyl]benzamide 859166-25-9P, 4-(3-Cyclopentylindole-1-sulfonyl)-N-(piperidin-1-yl)benzamide 859166-26-0P, 4-(3-Phenylindole-1-sulfonyl)-N-(piperidin-1-yl)benzamide 859166-27-1P, N-((1S,2R)-2-Hydroxycyclohexyl)-4-(3-phenylindole-1-sulfonyl)benzamide 859166-28-2P, N-((1R,2S)-2-Hydroxycyclohexyl)-4-(3-phenylindole-1-sulfonyl)benzamide 859166-29-3P, N-((1S,2S)-2-Hydroxycyclohexyl)-4-(3-phenylindole-1-sulfonyl)benzamide 859166-31-7P, N-((1R,2R)-2-Hydroxycyclohexyl)-4-(3-phenylindole-1-sulfonyl)benzamide 859166-33-9P 859166-34-0P, N-[[1-(4-Fluorophenyl)azetidin-3-yl]methyl]-4-(3-phenylindole-1-sulfonyl)benzamide 859166-35-1P, [3-[[(6-Fluoropyridin-2-yl)amino]methyl]azetidin-1-yl][4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859166-36-2P, [4-(3-Phenylindole-1-sulfonyl)phenyl][3-[[(pyrimidin-2-yl)amino]methyl]azetidin-1-yl]methanone 859166-37-3P, N,N-Dimethyl-N'-[[1-[4-(3-phenylindole-1-sulfonyl)benzoyl]azetidin-3-yl]methyl]urea 859166-38-4P 859166-39-5P, [3-[(4-Fluorobenzylamino)methyl]azetidin-1-yl][4-(3-phenylindole-1-sulfonyl)phenyl]methanone 859166-41-9P, 3-[4-(3-Phenylindole-1-sulfonyl)benzoylamino]azetidine-1-carboxylic acid methyl ester 859166-42-0P, (R)-[1-[4-(3-Phenylindole-1-sulfonyl)benzoyl]pyrrolidin-3-yl]carbamic acid methyl ester 859166-44-2P, (S)-[1-[4-(3-Phenylindole-1-sulfonyl)benzoyl]pyrrolidin-3-yl]carbamic acid methyl ester 859166-46-4P, [[1-[4-(3-Phenylindole-1-sulfonyl)benzoyl]azetidin-3-yl]methyl]carbamic acid methyl ester 859166-48-6P, [1-[4-(3-Phenylindole-1-sulfonyl)benzoyl]azetidin-3-yl]carbamic acid methyl ester 859166-50-0P, N-(4-Fluorobenzyl)-4-[3-(pyridin-3-yl)indole-1-sulfonyl]benzamide hydrochloride 859166-51-1P, N-(4-Fluorobenzyl)-4-[3-(pyridin-2-yl)indole-1-sulfonyl]benzamide hydrochloride 859166-52-2P, N-(4-Fluorobenzyl)-4-[3-(6-methoxypyridin-3-yl)indole-1-sulfonyl]benzamide 859166-53-3P, N-(4-Fluorobenzyl)-4-[3-(6-fluoropyridin-3-yl)indole-1-sulfonyl]benzamide 859166-54-4P, 4-[3-(5-Chlorothiophen-2-yl)indole-1-sulfonyl]-N-(4-fluorobenzyl)benzamide 859166-55-5P, N-(4-Fluorobenzyl)-4-((3-Cyclopropylindole-1-yl)sulfonyl)benzamide 859166-56-6P, N-(4-Fluorobenzyl)-4-[3-(thiophen-3-yl)indole-1-sulfonyl]benzamide 859166-57-7P, 4-[3-(2-Chlorophenyl)indole-1-sulfonyl]-N-(4-fluorobenzyl)benzamide 859166-58-8P, N-(4-Fluorobenzyl)-4-[3-(2-fluoropyridin-3-yl)indole-1-sulfonyl]benzamide 859166-59-9P, N-(4-Fluorobenzyl)-4-[3-(pyridin-4-yl)indole-1-sulfonyl]benzamide 859166-60-2P, N-(4-Fluorobenzyl)-4-[3-(thiophen-2-yl)indole-1-sulfonyl]benzamide 859166-61-3P, N-(4-Fluorobenzyl)-4-[3-(2-fluorophenyl)indole-1-sulfonyl]benzamide 859166-62-4P, N-(4-Fluorobenzyl)-4-[3-(3-fluorophenyl)indole-1-sulfonyl]benzamide 859166-63-5P, N-(4-Fluorobenzyl)-4-[3-(4-fluorophenyl)indole-1-sulfonyl]benzamide 859166-64-6P, N-(4-Fluorobenzyl)-4-[3-(furan-3-yl)indole-1-sulfonyl]benzamide 859166-65-7P, N-(4-Fluorobenzyl)-4-[3-(2-methylphenyl)indole-1-sulfonyl]benzamide 859166-66-8P, 4-[3-(4-Chlorophenyl)indole-1-sulfonyl]-N-(4-fluorobenzyl)benzamide 859166-67-9P, N-(4-Fluorobenzyl)-4-[3-(3-chlorophenyl)indole-1-sulfonyl]benzamide 859166-68-0P, N-(4-Fluorobenzyl)-4-[3-(isoquinolin-4-yl)indole-1-sulfonyl]benzamide 859166-69-1P, N-(4-Fluorobenzyl)-4-[3-(3-methylphenyl)indole-1-sulfonyl]benzamide 859166-70-4P, N-(4-Fluorobenzyl)-4-[3-(3-

methoxyphenyl)indole-1-sulfonyl]benzamide 859166-71-5P, N-(4-Fluorobenzyl)-4-[3-(furan-2-yl)indole-1-sulfonyl]benzamide 859166-72-6P, N-(4-Fluorobenzyl)-4-[3-(5-methylthiophen-2-yl)indole-1-sulfonyl]benzamide 859166-73-7P, N-(4-Fluorobenzyl)-4-[3-(p-tolyl)indole-1-sulfonyl]benzamide 859166-74-8P, N-(4-Fluorobenzyl)-4-[3-(quinolin-6-yl)indole-1-sulfonyl]benzamide 859166-75-9P, 4-[3-[4-(Dimethylamino)phenyl]indole-1-sulfonyl]-N-(4-fluorobenzyl)benzamide hydrochloride 859166-76-0P, N-(4-Fluorobenzyl)-4-[3-(3-fluoropyridin-4-yl)indol-1-sulfonyl]benzamide 859166-79-3P, N-(4-Fluorobenzyl)-4-[3-(pyrimidin-5-yl)indole-1-sulfonyl]benzamide hydrochloride 859166-80-6P, N-(4-Fluorobenzyl)-4-[3-(pyrazin-2-yl)indole-1-sulfonyl]benzamide 859166-81-7P, N-(4-Fluorobenzyl)-4-(3-phenylindole-1-sulfonyl)benzamide 859166-82-8P, 4-(3-Cyclopentylindole-1-sulfonyl)-N-(tetrahydropyran-4-yl)benzamide 859166-83-9P, 4-(3-Cyclopentylindole-1-sulfonyl)-N-[(tetrahydropyran-4-yl)methyl]benzamide 859166-86-2P, N-[(5-Fluoropyridin-2-yl)methyl]-4-(3-phenylindole-1-sulfonyl)benzamide 859166-88-4P, N-(4-Fluorobenzyl)-4-((3-phenylpyrrolo[2,3-b]pyridine-1-yl)sulfonyl)benzamide 859166-89-5P, N-(4-Fluorobenzyl)-4-[3-[2-(piperidin-1-yl)acetyl]indole-1-sulfonyl]benzamide 859166-90-8P, 4-(3-Cyclohexylindole-1-sulfonyl)-N-(4-fluorobenzyl)benzamide 859166-91-9P, 4-(3-Cyclohexylindole-1-sulfonyl)-N-[(tetrahydropyran-4-yl)methyl]benzamide 859166-92-0P, 4-(3-Cyclohexylindole-1-sulfonyl)-N-(tetrahydropyran-4-yl)benzamide 859166-93-1P, 4-[3-(3,3-Difluorocyclopentyl)indole-1-sulfonyl]-N-(tetrahydropyran-4-yl)benzamide 859166-94-2P, 4-[3-(3,3-Difluorocyclopentyl)indole-1-sulfonyl]-N-[(tetrahydropyran-4-yl)methyl]benzamide 859166-95-3P, N-(4-Fluoro-3-methoxybenzyl)-4-[3-(piperidin-1-yl)indole-1-sulfonyl]benzamide Hydrochloride 859166-96-4P, 4-[[4-(3-Phenylindole-1-sulfonyl)benzoylamino]methyl]-N,N-dimethylbenzamide 859166-97-5P , 4-(3-Cyclopentylindazole-1-sulfonyl)-N-(4-fluorobenzyl)benzamide 859166-98-6P, 4-(3-Cyclopentylindazole-1-sulfonyl)-N-(tetrahydropyran-4-yl)benzamide 859166-99-7P, 4-(3-Cyclopentylindazole-1-sulfonyl)-N-[(tetrahydropyran-4-yl)methyl]benzamide 859167-01-4P, 4-(3-Cyclopentylindazole-1-sulfonyl)-N-isobutylbenzamide 859167-03-6P, 4-(3-Cyclopentylindazole-1-sulfonyl)-N-[(cyclopropyl)methyl]benzamide 859167-05-8P, (R)-4-(3-Cyclopentylindazole-1-sulfonyl)-N-((tetrahydrofuran-2-yl)methyl)benzamide 859167-06-9P, (S)-4-(3-Cyclopentylindazole-1-sulfonyl)-N-((tetrahydrofuran-2-yl)methyl)benzamide 859167-07-0P, 4-[3-(Tetrahydropyran-4-yl)indole-1-sulfonyl]-N-[(tetrahydropyran-2-yl)methyl]benzamide 859167-08-1P, 4-(3-Phenylindole-1-sulfonyl)-N-[(tetrahydropyran-2-yl)methyl]benzamide 859167-09-2P, (R)-4-(3-Cyclopentylindole-1-sulfonyl)-N-[(tetrahydropyran-2-yl)methyl]benzamide 859167-10-5P , (S)-4-(3-Cyclopentylindole-1-sulfonyl)-N-[(tetrahydropyran-2-yl)methyl]benzamide 859167-12-7P, (R)-4-(3-Phenylindole-1-sulfonyl)-N-[(tetrahydrofuran-3-yl)methyl]benzamide 859167-14-9P , (S)-4-(3-Phenylindole-1-sulfonyl)-N-[(tetrahydrofuran-3-yl)methyl]benzamide 859167-16-1P, 4-(3-Cyclopentylindole-1-sulfonyl)-N-isobutylbenzamide 859167-18-3P, N-(4-Fluorobenzyl)-4-(3-isopropylindole-1-sulfonyl)benzamide 859167-20-7P, N-[(Cyclopropyl)methyl]-4-(3-isopropylindole-1-sulfonyl)benzamide 859167-22-9P, 4-((3-Cyclopentyl-2,3-dihydroindole-1-yl)sulfonyl)-N-(4-fluorobenzyl)benzamide 859167-24-1P, N-(4-Fluorobenzyl)-4-((3-methyl-2,3-dihydroindole-1-yl)sulfonyl)benzamide 859167-26-3P, 4-[3-(3-Cyanophenyl)indole-1-sulfonyl]-N-(4-fluorobenzyl)benzamide 859167-28-5P, N-(4-Fluorobenzyl)-4-[3-(thiazol-2-yl)indole-1-sulfonyl]benzamide 859167-30-9P, 4-(3-Cyclopentylindole-1-sulfonyl)-N-(5-fluoropyridin-2-ylmethyl)benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonyl-substituted indoles as CB1 receptor modulators)

RN 394228-83-2 CAPLUS
CN Morpholine, 4-[4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 394228-85-4 CAPLUS
CN Piperidine, 1-[4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 439128-75-3 CAPLUS
CN Piperazine, 1-[4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 859164-91-3 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[(3-phenyl-1H-pyrrolo[3,2-c]pyridin-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859164-93-5 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[(3-propyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 859164-94-6 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-(1H-pyrrolo[2,3-b]pyridin-1-ylsulfonyl)- (9CI) (CA INDEX NAME)




RN 859164-95-7 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-(1H-indol-1-ylsulfonyl)- (9CI) (CA INDEX NAME)




RN 859164-97-9 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(2-methoxycyclohexyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 859164-98-0 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(1-methyl-4-piperidinyl)-1H-indazol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859164-99-1 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[(3-phenyl-1H-indazol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-00-7 CAPLUS
CN Benzamide, 4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859165-02-9 CAPLUS
CN Benzamide, 4-[(3-acetyl-1H-indol-1-yl)sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859165-03-0 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(trifluoromethyl)-1H-indazol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-05-2 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-[(4-methyl-1-piperazinyl)carbonyl]-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-06-3 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(1-methyl-2-piperidinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-07-4 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(4-morpholinylacetyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-08-5 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-[(tetrahydro-2-furanyl)carbonyl]-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-09-6 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(1-methyl-4-piperidinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-10-9 CAPLUS
CN Benzamide, 4-[[3-(3,3-difluorocyclopentyl)-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 859165-11-0 CAPLUS
CN Benzamide, 4-[(3-ethyl-2,3-dihydro-3-methyl-1H-indol-1-yl)sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859165-17-6 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(4-morpholinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-18-7 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(4-methyl-1-piperazinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-19-8 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(1-piperidinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-20-1 CAPLUS
CN Benzamide, 4-[[3-(1,1-dimethylethyl)-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859165-21-2 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(1-methylcyclopentyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-22-3 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(1-piperidinyl)-1H-indazol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-23-4 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(4-morpholinyl)-1H-indazol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-24-5 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(3-hydroxycyclopentyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-27-8 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(tetrahydro-3-furanyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-29-0 CAPLUS
CN Benzamide, 4-[[(3R)-2,3-dihydro-3-phenyl-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859165-30-3 CAPLUS
CN Benzamide, 4-[[(3S)-2,3-dihydro-3-phenyl-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859165-31-4 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-42-7 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-(pyrazinylmethyl)- (9CI) (CA INDEX NAME)



RN 859165-43-8 CAPLUS
CN Benzamide, N-[(4-cyanophenyl)methyl]-4-[[3-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-44-9 CAPLUS
CN Azetidine, 2-phenyl-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-45-0 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-(2-pyrimidinylmethyl)-(9CI) (CA INDEX NAME)



RN 859165-46-1 CAPLUS
CN Piperidine, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 859165-47-2 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-(3-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 859165-48-3 CAPLUS
CN Benzamide, N-[(5-fluoro-3-pyridinyl)methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 859165-49-4 CAPLUS
CN Benzamide, N-[(5-fluoro-2-pyridinyl)methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 859165-51-8 CAPLUS
CN Benzamide, N-[[(1R,2R)-2-hydroxycyclohexyl]methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 859165-52-9 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-[[(2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859165-53-0 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-[[(2R)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859165-54-1 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 859165-55-2 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 859165-56-3 CAPLUS
CN Benzamide, N-[(1R,2R)-2-hydroxycyclohexyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 859165-59-6 CAPLUS
CN Piperidine, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 859165-60-9 CAPLUS
CN Piperidine, 4,4-difluoro-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-61-0 CAPLUS
CN Piperidine, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-62-1 CAPLUS
CN Pyrrolidine, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-63-2 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 859165-64-3 CAPLUS
CN Benzamide, N,N-dimethyl-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-65-4 CAPLUS
CN 4-Piperidinone, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-66-5 CAPLUS
CN 3-Piperidinol, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-67-6 CAPLUS
CN Morpholine, 4-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-68-7 CAPLUS
CN 2-Piperidinemethanol, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-69-8 CAPLUS
CN 3-Piperidinemethanol, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-70-1 CAPLUS
CN Benzamide, N-(trans-4-hydroxycyclohexyl)-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 859165-71-2 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-(3-pyridazinylmethyl)- (9CI) (CA INDEX NAME)



RN 859165-72-3 CAPLUS
CN Benzamide, N-[1-(4-fluorophenyl)-4-piperidinyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-73-4 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-[(1-phenyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 859165-74-5 CAPLUS
CN Benzamide, N-[(3R)-1-(4-fluorophenyl)-3-pyrrolidinyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859165-75-6 CAPLUS
CN Benzamide, N-[(3S)-1-(4-fluorophenyl)-3-pyrrolidinyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859165-76-7 CAPLUS
CN Benzamide, N-[1-(4-fluorophenyl)-3-azetidinyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-77-8 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 859165-78-9 CAPLUS
CN Benzamide, N-(2-methoxyethyl)-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-79-0 CAPLUS
CN Benzamide, N-[2-(1-methylethoxy)ethyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-80-3 CAPLUS
CN Benzamide, N-(2-ethoxyethyl)-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-81-4 CAPLUS
CN Benzoic acid, 4-[[[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 859165-82-5 CAPLUS
CN Benzamide, N-[(3-methoxyphenyl)methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-83-6 CAPLUS
CN Benzamide, N-[[4-(dimethylamino)phenyl]methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-84-7 CAPLUS
CN Benzamide, N-[(4-aminophenyl)methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-85-8 CAPLUS
CN 2-Pyrrolidinemethanamine, N-phenyl-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-87-0 CAPLUS
CN Azetidine, 3-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-89-2 CAPLUS
CN Benzamide, N-cyclobutyl-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-90-5 CAPLUS
CN 1-Azetidinecarboxylic acid, 3-[[[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 859165-91-6 CAPLUS
CN 3-Azetidinemethanol, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859165-92-7 CAPLUS
CN Benzamide, N-[[(2R)-tetrahydro-2-furanyl]methyl]-4-[[3-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859165-93-8 CAPLUS
CN Benzamide, N-(2-methoxycyclohexyl)-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 859165-94-9 CAPLUS
CN Benzamide, N-[1-(4-fluorophenyl)-3-pyrrolidinyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 859165-95-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 859165-96-1 CAPLUS
CN Piperidine, 4-(3-fluorophenyl)-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 859165-97-2 CAPLUS
CN Benzamide, 4-[[3-(2-fluoro-3-pyridinyl)-1H-indol-1-yl]sulfonyl]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 859165-98-3 CAPLUS
CN Benzamide, N-cyclobutyl-4-[[3-(2-fluoro-3-pyridinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859165-99-4 CAPLUS
CN Benzamide, N-(cyclopropylmethyl)-4-[[3-(2-fluoro-3-pyridinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-00-0 CAPLUS
CN Benzamide, 4-[[3-(6-fluoro-3-pyridinyl)-1H-indol-1-yl]sulfonyl]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-01-1 CAPLUS
CN Benzamide, N-(cyclopropylmethyl)-4-[[3-(6-fluoro-3-pyridinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-02-2 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)



RN 859166-03-3 CAPLUS
CN Benzamide, N-cyclobutyl-4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-04-4 CAPLUS
CN Azetidine, 1-[4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859166-05-5 CAPLUS
CN Benzamide, N-[(5-cyano-3-pyridinyl)methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-06-6 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]-N-[[(2R)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859166-07-7 CAPLUS
CN Benzamide, N-(cyclopropylmethyl)-4-[[3-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-09-9 CAPLUS
CN Benzamide, N-[(4-cyanophenyl)methyl]-4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-10-2 CAPLUS
CN Benzamide, N-[(4-cyanophenyl)methyl]-4-[(3-cyclopropyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-12-4 CAPLUS
CN Benzamide, N-(2-methylpropyl)-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-13-5 CAPLUS
CN Benzamide, N-(3-methylbutyl)-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-14-6 CAPLUS
CN Benzoic acid, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-, 2-(2-methylbutyl)hydrazide (9CI) (CA INDEX NAME)



RN 859166-15-7 CAPLUS
CN Benzamide, 4-[(3-cyclopropyl-1H-indol-1-yl)sulfonyl]-N-[(5-fluoro-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-16-8 CAPLUS
CN Benzamide, 4-[(3-cyclopropyl-1H-indol-1-yl)sulfonyl]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-17-9 CAPLUS
CN Benzamide, 4-[(3-cyclopropyl-1H-indol-1-yl)sulfonyl]-N-[2-(1-methylethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 859166-18-0 CAPLUS
CN Benzamide, N-[(4-cyanophenyl)methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-19-1 CAPLUS
CN Benzamide, N-[(5-fluoro-2-pyridinyl)methyl]-4-[[3-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-20-4 CAPLUS
CN Benzamide, 4-[[3-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl]sulfonyl]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-21-5 CAPLUS
CN Benzamide, N-cyclobutyl-4-[[3-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-22-6 CAPLUS

CN Benzamide, N-[(5-fluoro-3-pyridinyl)methyl]-4-[[3-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-23-7 CAPLUS
CN Benzamide, N-(cyclopropylmethyl)-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-24-8 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 859166-25-9 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 859166-26-0 CAPLUS

CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 859166-27-1 CAPLUS
CN Benzamide, N-[(1S,2R)-2-hydroxycyclohexyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859166-28-2 CAPLUS
CN Benzamide, N-[(1R,2S)-2-hydroxycyclohexyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859166-29-3 CAPLUS
CN Benzamide, N-[(1S,2S)-2-hydroxycyclohexyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859166-31-7 CAPLUS
CN Benzamide, N-[(1R,2R)-2-hydroxycyclohexyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859166-33-9 CAPLUS
CN Carbamic acid, dimethyl-, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-3-azetidinyl ester (9CI) (CA INDEX NAME)




RN 859166-34-0 CAPLUS
CN Benzamide, N-[[1-(4-fluorophenyl)-3-azetidinyl]methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 859166-35-1 CAPLUS
CN 3-Azetidinemethanamine, N-(6-fluoro-2-pyridinyl)-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859166-36-2 CAPLUS
CN 3-Azetidinemethanamine, 1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 859166-37-3 CAPLUS
CN 3-Azetidinemethanamine, N-[(dimethylamino)carbonyl]-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859166-38-4 CAPLUS
CN 3-Azetidinemethanamine, N-[(dimethylamino)thioxomethyl]-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859166-39-5 CAPLUS
CN 3-Azetidinemethanamine, N-[(4-fluorophenyl)methyl]-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 859166-41-9 CAPLUS
CN 1-Azetidinecarboxylic acid, 3-[[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 859166-42-0 CAPLUS
CN Carbamic acid, [(3R)-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859166-44-2 CAPLUS
CN Carbamic acid, [(3S)-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859166-46-4 CAPLUS
CN Carbamic acid, [[1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-3-azetidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 859166-48-6 CAPLUS
CN Carbamic acid, [1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]-3-azetidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 859166-50-0 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(3-pyridinyl)-1H-indol-1-yl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 859166-51-1 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(2-pyridinyl)-1H-indol-1-yl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 859166-52-2 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(6-methoxy-3-pyridinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-53-3 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(6-fluoro-3-pyridinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-54-4 CAPLUS
CN Benzamide, 4-[[3-(5-chloro-2-thienyl)-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-55-5 CAPLUS
CN Benzamide, 4-[(3-cyclopropyl-1H-indol-1-yl)sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-56-6 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(3-thienyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-57-7 CAPLUS

CN Benzamide, 4-[[3-(2-chlorophenyl)-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-58-8 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(2-fluoro-3-pyridinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-59-9 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(4-pyridinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-60-2 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(2-thienyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-61-3 CAPLUS
CN Benzamide, 4-[[3-(2-fluorophenyl)-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-62-4 CAPLUS
CN Benzamide, 4-[[3-(3-fluorophenyl)-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-63-5 CAPLUS
CN Benzamide, 4-[[3-(4-fluorophenyl)-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-64-6 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(3-furanyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-65-7 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(2-methylphenyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-66-8 CAPLUS
CN Benzamide, 4-[[3-(4-chlorophenyl)-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-67-9 CAPLUS
CN Benzamide, 4-[[3-(3-chlorophenyl)-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-68-0 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(4-isoquinolinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 859166-69-1 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(3-methylphenyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-70-4 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(3-methoxyphenyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-71-5 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(2-furanyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-72-6 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(5-methyl-2-thienyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-73-7 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(4-methylphenyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-74-8 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(6-quinolinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 859166-75-9 CAPLUS
CN Benzamide, 4-[[3-[4-(dimethylamino)phenyl]-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 859166-76-0 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(3-fluoro-4-pyridinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-79-3 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(5-pyrimidinyl)-1H-indol-1-yl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 859166-80-6 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[(3-pyrazinyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-81-7 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-82-8 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 859166-83-9 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-86-2 CAPLUS
CN Benzamide, N-[(5-fluoro-2-pyridinyl)methyl]-4-[(3-phenyl-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-88-4 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-89-5 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(1-piperidinylacetyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859166-90-8 CAPLUS
CN Benzamide, 4-[(3-cyclohexyl-1H-indol-1-yl)sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-91-9 CAPLUS
CN Benzamide, 4-[(3-cyclohexyl-1H-indol-1-yl)sulfonyl]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-92-0 CAPLUS
CN Benzamide, 4-[(3-cyclohexyl-1H-indol-1-yl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 859166-93-1 CAPLUS
CN Benzamide, 4-[[3-(3,3-difluorocyclopentyl)-1H-indol-1-yl]sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 859166-94-2 CAPLUS
CN Benzamide, 4-[[3-(3,3-difluorocyclopentyl)-1H-indol-1-yl]sulfonyl]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-95-3 CAPLUS
CN Benzamide, N-[(4-fluoro-3-methoxyphenyl)methyl]-4-[[3-(1-piperidinyl)-1H-indol-1-yl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 859166-96-4 CAPLUS
CN Benzamide, N,N-dimethyl-4-[[[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 859166-97-5 CAPLUS

CN Benzamide, 4-[(3-cyclopentyl-1H-indazol-1-yl)sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859166-98-6 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indazol-1-yl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 859166-99-7 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indazol-1-yl)sulfonyl]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 859167-01-4 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indazol-1-yl)sulfonyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 859167-03-6 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indazol-1-yl)sulfonyl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)



RN 859167-05-8 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indazol-1-yl)sulfonyl]-N-[[(2R)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859167-06-9 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indazol-1-yl)sulfonyl]-N-[[(2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859167-07-0 CAPLUS
CN Benzamide, 4-[[3-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 859167-08-1 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 859167-09-2 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]-N-[[(2R)-tetrahydro-2H-pyran-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859167-10-5 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]-N-[[(2S)-tetrahydro-2H-pyran-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859167-12-7 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-[[(3R)-tetrahydro-3-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859167-14-9 CAPLUS
CN Benzamide, 4-[(3-phenyl-1H-indol-1-yl)sulfonyl]-N-[[(3S)-tetrahydro-3-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859167-16-1 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 859167-18-3 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(1-methylethyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859167-20-7 CAPLUS
CN Benzamide, N-(cyclopropylmethyl)-4-[[3-(1-methylethyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859167-22-9 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859167-24-1 CAPLUS
CN Benzamide, 4-[(2,3-dihydro-3-methyl-1H-indol-1-yl)sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859167-26-3 CAPLUS
CN Benzamide, 4-[[3-(3-cyanophenyl)-1H-indol-1-yl]sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859167-28-5 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(2-thiazolyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 859167-30-9 CAPLUS
CN Benzamide, 4-[(3-cyclopentyl-1H-indol-1-yl)sulfonyl]-N-[(5-fluoro-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



IT 859165-26-7, N-(Fluorobenzyl)-4-(3-iodoindole-1-sulfonyl)benzamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylsulfonyl-substituted indoles as CB1 receptor modulators)
RN 859165-26-7 CAPLUS
CN Benzamide, 4-[(3-iodo-1H-indol-1-yl)sulfonyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT 859164-74-2P, N-(4-Fluorobenzyl)-4-(3-iodoindole-1-

sulfonyl)benzamide 859164-75-3P, N-(4-Fluorobenzyl)-4-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)indole-1-sulfonyl]benzamide 859164-77-5P, 4-(3-Chloroindazole-1-sulfonyl)-N-(4-fluorobenzyl)benzamide 859164-90-2P, 4-[[4-(3-Phenylindole-1-sulfonyl)benzoylamino]methyl]benzoic acid 859166-40-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylsulfonyl-substituted indoles as CB1 receptor modulators)

RN 859164-74-2 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[(3-iodo-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 859164-75-3 CAPLUS
CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)







RN 859164-77-5 CAPLUS
CN Benzamide, 4-[(3-chloro-1H-indazol-1-yl)sulfonyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 859164-90-2 CAPLUS
CN Benzoic acid, 4-[[[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 859166-40-8 CAPLUS
CN 3-Azetidinemethanamine, N-[(4-fluorophenyl)methylene]-1-[4-[(3-phenyl-1H-indol-1-yl)sulfonyl]benzoyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:428206 CAPLUS
DOCUMENT NUMBER: 142:457124
TITLE: Adenosine A2A receptor antagonists containing benzofuran derivatives, prophylactic or therapeutic agents containing the derivatives, and pharmaceuticals comprising the derivatives and antiparkinsonian drugs, antidepressants, etc.
INVENTOR(S): Ozawa, Tomonaga; Nakamura, Tetsuya; Misawa, Keiko; Sakamoto, Shigeru; Onoda, Hideki
PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 2005126374 | A | 20050519 | JP 2003-363973 | 20031024 |
| PRIORITY APPLN. INFO.: | | | JP 2003-363973 | 20031024 |

OTHER SOURCE(S): MARPAT 142:457124
GI



I

AB A2A receptor antagonists, useful for treatment of locomotive diseases such as parkinsonism, depression, cognitive dysfunction, cerebral ischemia, etc., contain benzofuran derivs. I [R1 = H, lower alky; R2 = (a) cycloalkyl, (b) Ph, naphthyl, aralkyl, aryloxy-lower alkyl, arylsulfanyl-lower alkyl, optionally substituted with 1-3 X1-X3, (c) (un)substituted heterocyclyl including 2-furyl, 2-benzothienyl, benzothiazolyl, etc.; X1-X3 = halo, lower (halo)alkyl, lower alkoxy, carboxy, lower alkoxycarbonyl, lower acyl, benzoyl, NO2, cyano, etc.] or their pharmacol. acceptable salts. Also claimed are prophylactic or therapeutic agents for A2A receptor-related diseases containing I or their salts. Thus, I (R1 = H, R2 = Q) (II) inhibited human adenosine adenosine A2A receptor-mediated AMP production at Ki 12 nM. II also shortened duration of haloperidol-induced catalepsy in mice.

IT 399000-63-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A2A receptor antagonists containing benzofuran derivs. for treatment of locomotor disorders, depression, cognitive dysfunction, cerebral ischemia, etc.)

RN 399000-63-6 CAPLUS
CN 2-Benzofurancarboxamide, 3-[[4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:395267 CAPLUS
DOCUMENT NUMBER: 142:463596
TITLE: Preparation of indole derivatives as PGD2 antagonists
INVENTOR(S): Middlemiss, David; Ashton, Mark Richard; Boyd, Edward Andrew; Brookfield, Frederick Arthur; Armer, Richard Edward
PATENT ASSIGNEE(S): Oxagen Limited, UK
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005040112 | A1 | 20050506 | WO 2004-GB4337 | 20041013 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
GB 2003-24083 A 20031014
GB 2004-3334 A 20040214
GB 2004-6963 A 20040327

OTHER SOURCE(S): CASREACT 142:463596; MARPAT 142:463596
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1, R2, R3, and R4 independently = H, halo, alkyl, etc.; R5 and R6 independently = H, alkyl or R5 and R6 together with carbon atom to which they are attached 3-7-membered cycloalkyl; R7 = H, alkyl; R8 = alkyl, alkenyl, alkynyl, etc.; R9 = H, alkyl, aryl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as PGD2 antagonists. Thus, e.g., II was prepared by sulfonylation of (5-fluoro-1H-indol-3-yl)-acetic acid Et ester with 4-fluorobenzene

sulfonyl chloride and subsequent hydrolysis of the Et ester. The activity of I towards CRTH2 receptors was evaluated in radioligand binding assays and it revealed that selected compds. of the invention displayed Ki values in the range of 15 up to 3050 nM. I as PGD2 antagonists should prove useful in the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis. Pharmaceutical compns. comprising I are disclosed.

IT 851448-28-7P 851448-43-6P 851448-47-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. as PGD antagonists)

RN 851448-28-7 CAPLUS
CN 1H-Indole-3-acetic acid, 1-[[4-(aminocarbonyl)phenyl]sulfonyl]-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)



RN 851448-43-6 CAPLUS
CN 1H-Indole-3-acetic acid, 5-fluoro-2-methyl-1-[[4-[(methylamino)carbonyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 851448-47-0 CAPLUS
CN 1H-Indole-3-acetic acid, 1-[[4-[(dimethylamino)carbonyl]phenyl]sulfonyl]-5-fluoro-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:754409 CAPLUS
DOCUMENT NUMBER: 141:254525
TITLE: Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases

INVENTOR(S): Bailey, Thomas R.; Pevear, Daniel C.
PATENT ASSIGNEE(S): Viropharma, Incorporated, USA
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004078115 | A2 | 20040916 | WO 2004-US5471 | 20040225 |
| WO 2004078115 | A3 | 20060914 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2003-450854P P 20030228
OTHER SOURCE(S): MARPAT 141:254525

AB Methods of using benzothiazole derivs. and analogs, as well as pharmaceutical compns. containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the rotavirus. N-(4-Chlorobenzothiazol-2-yl)-4-(morpholine-4-sulfonyl)benzamide was prepared from 2-amino-4-chlorobenzothiazole.

IT 361170-45-8
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzothiazole compds., compns. and methods for treatment and prophylaxis of rotavirus infections and associated diseases)

RN 361170-45-8 CAPLUS
CN Benzamide, N-(6-chloro-2-benzothiazolyl)-4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:182873 CAPLUS
DOCUMENT NUMBER: 140:235499
TITLE: Preparation of aminoarylbenzoic acid derivatives as antibacterial agents for use as disinfectants and therapeutic agents
INVENTOR(S): Thorarensen, Atli; Ruble, Craig J.; Romero, Donna L.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2004018461 | A2 | 20040304 | WO 2003-US24791 | | 20030820 |
| WO 2004018461 | A3 | 20040826 | | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| AU 2003265382 | A1 | 20040311 | AU 2003-265382 | | 20030820 |
| US 2004142981 | A1 | 20040722 | US 2003-645799 | | 20030820 |
| PRIORITY APPLN. INFO.: | | | US 2002-405614P | P | 20020823 |
| | | | US 2002-413596P | P | 20020925 |
| | | | US 2002-430351P | P | 20021202 |
| | | | WO 2003-US24791 | W | 20030820 |

OTHER SOURCE(S): MARPAT 140:235499
GI




I




II

AB The title compds. I [X = NH; Y = CO, CS, C=NCN, or X and Y together form an alkene, or cycloalkyl; R1 = (un)substituted-heterocycle, -heterocyclylcarbonyl, NHSO2R3; R2 = electron withdrawing group; R3 = H, (un)substituted alkyl or aryl; R4 = (un)substituted aryl with provisions] and their pharmaceutically acceptable salts are prepared and disclosed as antibacterial agents. Thus, e.g., II was prepared by amidation of 3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl chloride (preparation given) with 3-(2-amino-5-bromophenyl)-1,2,4-oxadiazol-5(4H)-one. In assays, the min. inhibitory concentration values (μg/mL) ranged from 0.125 - >128. As antibacterial agents I are useful for sterilization, sanitation, antisepsis, and disinfection.

IT 666859-60-5P 666859-69-4P 666859-70-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of aminoarylbenzoic acid derivs. as antibacterial agents)

RN 666859-60-5 CAPLUS
CN Benzamide, N-(4-bromo-2-cyanophenyl)-4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 666859-69-4 CAPLUS
CN Benzoic acid, 2-[[4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]-5-cyano-, methyl ester (9CI) (CA INDEX NAME)



RN 666859-70-7 CAPLUS
CN Benzoic acid, 2-[[4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]-5-cyano-, hydrazide (9CI) (CA INDEX NAME)



IT 666858-84-0P 666859-14-9P 666859-16-1P
666859-38-7P 666859-40-1P 666859-42-3P
666859-44-5P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of aminoarylbenzoic acid derivs. as antibacterial agents)

RN 666858-84-0 CAPLUS
CN Benzamide, N-[4-bromo-2-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]-4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 666859-14-9 CAPLUS
CN Benzamide, 4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[4-cyano-2-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 666859-16-1 CAPLUS
CN Benzamide, 4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[4-cyano-2-(4,5-dihydro-5-thioxo-1,3,4-oxadiazol-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 666859-38-7 CAPLUS
CN Benzamide, N-[4-bromo-2-(1H-tetrazol-5-yl)phenyl]-4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 666859-40-1 CAPLUS
CN Benzamide, N-[4-bromo-2-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]-4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 666859-42-3 CAPLUS
CN Benzamide, N-[4-bromo-2-(1H-tetrazol-5-yl)phenyl]-4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 666859-44-5 CAPLUS
CN Benzamide, N-[4-bromo-2-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)phenyl]-4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:182832 CAPLUS
DOCUMENT NUMBER: 140:235497
TITLE: Preparation of aminoarylbenzoic acid derivatives as antibacterial agents for use as disinfectants and therapeutic agents
INVENTOR(S): Thorarensen, Atli; Ruble, Craig J.; Romero, Donna L.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 359 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004018414 | A2 | 20040304 | WO 2003-US24797 | 20030822 |
| WO 2004018414 | A3 | 20040617 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2005113450 | A1 | 20050526 | US 2003-645732 | 20030820 |
| AU 2003282779 | A1 | 20040311 | AU 2003-282779 | 20030822 |
| PRIORITY APPLN. INFO.: | | | US 2002-405464P P | 20020823 |
| | | | WO 2003-US24797 W | 20030822 |

OTHER SOURCE(S): MARPAT 140:235497
GI



I



II

AB The title compds. I [X = NH; Y = CO, CS, C=NCN, or X and Y together form an alkene, or cycloalkyl; R1 = CO2H; R2 = electron withdrawing group; R4 = (un)substituted aryl with provisions] and their pharmaceutically acceptable salts are prepared and disclosed as antibacterial agents. Thus, e.g., II was prepared by conversion of 4-(chlorosulfonyl)benzoic acid to the acid chloride then amidated with Me 2-amino-5-bromobenzoate with subsequent reaction with di-Et amine and hydrolysis to give the benzoic acid moiety. In assays, the min. inhibitory concentration values (μg/mL) ranged from 0.125 - >128. As antibacterial agents I are useful for sterilization, sanitation, antisepsis, and disinfection. Claims for therapeutic use of I as an antibacterial agent are made.

IT 668261-19-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of aminoarylbenzoic acid derivs. as antibacterial agents)

RN 668261-19-6 CAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(5-fluoro-1H-indol-1-yl)sulfonyl]benzoyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT 668261-14-1P 668261-15-2P 668261-16-3P
668261-18-5P 668263-81-8P 668263-89-6P
668263-90-9P 668263-91-0P 668263-92-1P
668263-96-5P 668264-00-4P 668264-17-3P
668264-18-4P 668265-57-4P 668267-85-4P
668268-02-8P 668268-04-0P 668268-25-5P
668268-36-8P 668268-37-9P 668268-38-0P
668268-39-1P 668268-40-4P 668268-41-5P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of aminoarylbenzoic acid derivs. as antibacterial agents)

RN 668261-14-1 CAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668261-15-2 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(2,3-dihydro-5-methoxy-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668261-16-3 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(5-fluoro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668261-18-5 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(5-fluoro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668263-81-8 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-(1H-indol-1-ylsulfonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668263-89-6 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(5-chloro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668263-90-9 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(6-chloro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668263-91-0 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(6-chloro-5-fluoro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668263-92-1 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(6-fluoro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668263-96-5 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(5-methoxy-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668264-00-4 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-(1H-pyrrolo[2,3-b]pyridin-1-ylsulfonyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668264-17-3 CAPLUS
CN Benzoic acid, 2-[[4-[(6-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]-5-(1-oxohexyl)- (9CI) (CA INDEX NAME)



RN 668264-18-4 CAPLUS
CN Benzoic acid, 2-[[4-[(6-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]-5-(cyclopentylcarbonyl)- (9CI) (CA INDEX NAME)



RN 668265-57-4 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(6-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (CA INDEX NAME)



RN 668267-85-4 CAPLUS
CN Benzoic acid, 5-acetyl-2-[[4-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668268-02-8 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(6-chloro-5-fluoro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668268-04-0 CAPLUS
CN Benzoic acid, 5-bromo-2-[[4-[(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668268-25-5 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[[4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 668268-36-8 CAPLUS
CN Benzoic acid, 2-[[4-[(6-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]-5-iodo- (9CI) (CA INDEX NAME)



RN 668268-37-9 CAPLUS
CN Benzoic acid, 2-[[4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 668268-38-0 CAPLUS
CN Benzoic acid, 2-[[4-[(6-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]-5-(1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 668268-39-1 CAPLUS
CN Benzoic acid, 2-[[4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]-5-[(hydroxyimino)phenylmethyl]- (9CI) (CA INDEX NAME)



RN 668268-40-4 CAPLUS
CN Benzoic acid, 2-[[4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]-5-[(ethoxyimino)phenylmethyl]- (9CI) (CA INDEX NAME)



RN 668268-41-5 CAPLUS
CN Benzoic acid, 2-[[4-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl]amino]-5-[1-(ethoxyimino)-2-methylpropyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:904102 CAPLUS

DOCUMENT NUMBER: 136:37614
TITLE: Preparation of chiral heterocyclylcarbonylaminobicyclo heptanehydrocarboncarboxylic acids in remedy composition antagonistic to both PGD2 and TXA2 receptors
INVENTOR(S): Tanimoto, Norihiko; Arimura, Akinori
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 278 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001094309 | A1 | 20011213 | WO 2001-JP4430 | 20010528 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2001060627 | A5 | 20011217 | AU 2001-60627 | 20010528 |
| EP 1295872 | A1 | 20030326 | EP 2001-934363 | 20010528 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 2004024019 | A1 | 20040205 | US 2002-297065 | 20021202 |
| US 7084136 | B2 | 20060801 | | |

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | | JP 2000-166305 | A 20000602 |
| | | WO 2001-JP4430 | W 20010528 |

OTHER SOURCE(S): MARPAT 136:37614
GI




I




II

AB Title compds. [I; A = alkylene optionally having an unsatd. bond; R = COR1, CH2OCH3, CH2OH; R1 = OH, OCH3, NH2, NHSO2CH3; X1, X3 independently = optionally substituted aryl, optionally substituted heteroaryl; X2 =

single bond, CH2, S, SO2, CH2O, OCH2, CH2S, SCH2; Y = bicycloheptane] and pharmaceutically acceptable salts or solvates, having antagonistic effect on both thromboxane A2 and prostaglandin D2 receptors, are prepared Thus, the title compound II was prepared and biol. tested for TXA2 receptor antagonistic activity with IC50(μM) = 0.011 and PGD2 receptor antagonistic activity with IC50(μM) = 0.079.

IT 271773-08-1P
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of chiral heterocyclylcarbonylaminobicycloheptanehydrocarboncarboxylic acids in remedy composition as PGD2 and TXA2 receptors antagonists)

RN 271773-08-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(1H-indol-1-ylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:645983 CAPLUS
DOCUMENT NUMBER: 133:222579
TITLE: Preparation of [2.2.1] and [3.1.1]bicycloheptane antagonistic to both of PGD2/TXA2 receptors
INVENTOR(S): Honma, Tsunetoshi; Hiramatsu, Yoshiharu; Arimura, Akinori
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan
SOURCE: PCT Int. Appl., 251 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000053573 | A1 | 20000914 | WO 2000-JP1223 | 20000302 |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,

CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| EP 1176139 | A1 | 20020130 | EP 2000-906622 | | 20000302 |
| EP 1176139 | B1 | 20050518 | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | | |
| AT 295831 | T | 20050615 | AT 2000-906622 | | 20000302 |
| JP 3828364 | B2 | 20061004 | JP 2000-604014 | | 20000302 |
| US 7105564 | B1 | 20060912 | US 2001-936161 | | 20010910 |
| PRIORITY APPLN. INFO.: | | | JP 1999-62721 | A | 19990310 |
| | | | WO 2000-JP1223 | W | 20000302 |

OTHER SOURCE(S): MARPAT 133:222579

GI




I




AB Medicinal compns. containing the title compds. [I; ring Y = Q, Q1, Q2; R1 = CH2CH:CH(CH2)3CO2R2, CH:CH(CH2)3CO2R2; wherein R2 = H, alkyl; m = 0,1; p = 0,1; when p = 0, X1 and X3 are not linked to each other through X4; X1, X3 = (un)substituted aryl or heteroaryl; X2 = CH2, CH2CH2, CO, O, S, SO, SO2, NH, NHMe, C(:NOMe), N:N, CH:CH, CONH, NHCO, CH2NH, NHCH2, CH2O, OCH2, CH2S, SCH2, CH2SO2, SO2CH2, SO2NH, NHSO2; X4 = CH2, CH2CH2, CO, SO, SO2, CONH, NHCO, CH2NH, NHCH2, CH2O, OCH2, CH2S, SCH2, CH2SO2, SO2CH2, SO2NH, NHSO2], prodrugs or pharmaceutically acceptable salts thereof, or hydrate thereof antagonistic to both of thromboxane A2 and prostaglandin D2 receptors and medicinal compns. for the treatment of asthma and nasal obstruction are claimed. Thus, (5Z)-7-[(1R,2S,3S,4S)-3-aminobicyclo[2.2.1]hept-2-yl]-5-heptenoic acid Me ester was condensed with 5-(pyrrole-1-sulfonyl)thiophene-2-carboxylic acid using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzotriazole in THF under ice-cooling at 25° for 16 h, followed by saponification with a mixture of 4 N aqueous NaOH and THF and acidification with 5 N aqueous HCl to give title compound [II; R = 5-(pyrrole-1-sulfonyl)thiophene-2-carbonyl] (III). III and II [R = 2-(thiophen-2-ylthiomethyl)thiophen-5-yl] showed IC50 of 0.0043 and 0.001 μM, resp., for inhibiting the binding the [3H](+)-(5Z)-7-[3-endo-(phenylsulfonylamino)bicyclo[2.2.1]hept-2-exo-yl]heptenoic acid sodium salt to prostaglandin D2 receptor preparation from human peripheral blood platelet.

IT 271773-08-1P 271774-29-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [2.2.1] and [3.1.1]bicycloheptane as antagonists of PGD2/TXA2 receptors for treatment of asthma and nasal obstruction)

RN 271773-08-1 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(1H-indol-1-ylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 271774-29-9 CAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[4-(1H-indol-1-ylsulfonyl)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:368150 CAPLUS
DOCUMENT NUMBER: 133:12765
TITLE: Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect
INVENTOR(S): Yagami, Tatsuro; Honma, Tsunetoshi; Katsuura, Goro
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000030683 | A1 | 20000602 | WO 1999-JP6317 | 19991112 |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 1998-329862 A 19981119

OTHER SOURCE(S): MARPAT 133:12765

AB Compds. having TXA2 antagonism and/or a TXA2 synthase inhibitory effect, prodrugs thereof, pharmaceutically acceptable salts of the same or hydrates of the same, which show effects of inhibiting nerve cell denaturation caused by amyloid β protein and nerve cell death caused by axonotmesis, are useful as preventives and/or remedies for central nervous system diseases, preventives and/or remedies for nerve degeneration diseases, nerve cell denaturation inhibitors, amyloid β protein-induced nerve cell denaturation inhibitors, nerve cell death inhibitors, axonotmesis-induced nerve cell death inhibitors and, in particular, preventives and/or remedies for dementia of Alzheimer type.

IT 271773-08-1P 271774-29-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preventives and/or remedies for central nervous system diseases containing compds. having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect)

RN 271773-08-1 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[[4-(1H-indol-1-ylsulfonyl)benzoyl]amino]bicyclo[2.2.1]hept-2-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 271774-29-9 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3S,5S)-2-[[4-(1H-indol-1-ylsulfonyl)benzoyl]amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:11:19 ON 01 MAY 2007)

FILE 'REGISTRY' ENTERED AT 17:11:27 ON 01 MAY 2007
L1 STRUCTURE UPLOADED
L2 36 S L1
L3 673 S L1 FULL

FILE 'CAPLUS' ENTERED AT 17:12:24 ON 01 MAY 2007
L4 10 S L3 FULL

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 55.99 | 228.75 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -7.80 | -7.80 |

STN INTERNATIONAL LOGOFF AT 17:16:31 ON 01 MAY 2007